<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pediatric Renal Masses | Dr. Mikael Petrosyan</title>
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/theme/black.min.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/all.min.css">
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800;900&family=Playfair+Display:wght@700;800;900&display=swap" rel="stylesheet">
  <style>
    :root {
      --navy: #0a1628;
      --teal: #0ea5e9;
      --teal-dark: #0284c7;
      --emerald: #10b981;
      --amber: #f59e0b;
      --rose: #f43f5e;
      --purple: #8b5cf6;
      --slate: #94a3b8;
      --white: #f8fafc;
    }

    .reveal {
      font-family: 'Inter', -apple-system, sans-serif;
      font-size: 28px;
      color: var(--white);
    }

    .reveal .slides { text-align: left; }

    .reveal .slides section {
      padding: 40px 60px;
      height: 100%;
      box-sizing: border-box;
    }

    .reveal h1, .reveal h2, .reveal h3 {
      font-family: 'Playfair Display', serif;
      text-transform: none;
      letter-spacing: -0.02em;
      color: var(--white);
    }

    .reveal h1 { font-size: 2.8em; font-weight: 900; line-height: 1.1; }
    .reveal h2 { font-size: 1.8em; font-weight: 800; margin-bottom: 0.5em; }
    .reveal h3 { font-size: 1.3em; font-weight: 700; color: var(--teal); margin-bottom: 0.4em; }

    .reveal p, .reveal li { line-height: 1.6; font-weight: 400; }
    .reveal ul { list-style: none; padding: 0; }
    .reveal ul li { padding: 0.2em 0; padding-left: 1.5em; position: relative; }
    .reveal ul li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 0.65em;
      width: 8px;
      height: 8px;
      border-radius: 50%;
      background: var(--teal);
    }

    /* Title slide */
    .title-slide {
      text-align: center !important;
      display: flex !important;
      flex-direction: column;
      justify-content: center;
      align-items: center;
      background: radial-gradient(ellipse at 30% 50%, rgba(14,165,233,0.15), transparent 70%),
                  radial-gradient(ellipse at 70% 80%, rgba(139,92,246,0.1), transparent 60%);
    }

    .title-slide .subtitle {
      font-size: 1.4em;
      color: var(--teal);
      font-weight: 600;
      margin-top: 0.3em;
      letter-spacing: 0.05em;
    }

    .title-slide .author {
      font-size: 0.8em;
      color: var(--slate);
      margin-top: 2em;
      font-weight: 400;
    }

    .title-slide .author strong {
      color: var(--white);
      font-weight: 600;
      display: block;
      font-size: 1.2em;
      margin-bottom: 0.3em;
    }

    /* Section divider */
    .section-divider {
      text-align: center !important;
      display: flex !important;
      flex-direction: column;
      justify-content: center;
      align-items: center;
    }

    .section-divider h2 {
      font-size: 2.5em;
      background: linear-gradient(135deg, var(--teal), var(--purple));
      -webkit-background-clip: text;
      -webkit-text-fill-color: transparent;
      background-clip: text;
    }

    .section-divider .section-number {
      font-size: 5em;
      font-weight: 900;
      opacity: 0.08;
      position: absolute;
      top: 10%;
      right: 10%;
      font-family: 'Playfair Display', serif;
    }

    /* Stat cards */
    .stat-grid {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 20px;
      margin-top: 1em;
    }

    .stat-card {
      background: rgba(255,255,255,0.05);
      border: 1px solid rgba(255,255,255,0.1);
      border-radius: 16px;
      padding: 24px;
      text-align: center;
      transition: all 0.3s ease;
    }

    .stat-card:hover {
      background: rgba(14,165,233,0.1);
      border-color: var(--teal);
      transform: translateY(-2px);
    }

    .stat-card .number {
      font-size: 2.5em;
      font-weight: 900;
      background: linear-gradient(135deg, var(--teal), var(--emerald));
      -webkit-background-clip: text;
      -webkit-text-fill-color: transparent;
      background-clip: text;
    }

    .stat-card .label {
      font-size: 0.7em;
      color: var(--slate);
      margin-top: 0.3em;
      text-transform: uppercase;
      letter-spacing: 0.1em;
    }

    /* Two column layout */
    .two-col {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 40px;
      margin-top: 0.5em;
    }

    .three-col {
      display: grid;
      grid-template-columns: 1fr 1fr 1fr;
      gap: 20px;
      margin-top: 0.5em;
    }

    /* Info box */
    .info-box {
      background: rgba(14,165,233,0.1);
      border-left: 4px solid var(--teal);
      border-radius: 0 12px 12px 0;
      padding: 16px 20px;
      margin: 0.8em 0;
      font-size: 0.85em;
    }

    .warning-box {
      background: rgba(244,63,94,0.1);
      border-left: 4px solid var(--rose);
      border-radius: 0 12px 12px 0;
      padding: 16px 20px;
      margin: 0.8em 0;
      font-size: 0.85em;
    }

    .pearl-box {
      background: rgba(245,158,11,0.1);
      border-left: 4px solid var(--amber);
      border-radius: 0 12px 12px 0;
      padding: 16px 20px;
      margin: 0.8em 0;
      font-size: 0.85em;
    }

    /* Tags/pills */
    .tag {
      display: inline-block;
      padding: 4px 14px;
      border-radius: 20px;
      font-size: 0.65em;
      font-weight: 600;
      margin: 2px;
    }

    .tag-teal { background: rgba(14,165,233,0.2); color: var(--teal); }
    .tag-emerald { background: rgba(16,185,129,0.2); color: var(--emerald); }
    .tag-amber { background: rgba(245,158,11,0.2); color: var(--amber); }
    .tag-rose { background: rgba(244,63,94,0.2); color: var(--rose); }
    .tag-purple { background: rgba(139,92,246,0.2); color: var(--purple); }

    /* Table styling */
    .reveal table {
      width: 100%;
      border-collapse: collapse;
      font-size: 0.7em;
      margin-top: 0.5em;
    }

    .reveal table th {
      background: rgba(14,165,233,0.2);
      color: var(--teal);
      padding: 10px 14px;
      text-align: left;
      font-weight: 700;
      border-bottom: 2px solid var(--teal);
    }

    .reveal table td {
      padding: 8px 14px;
      border-bottom: 1px solid rgba(255,255,255,0.08);
    }

    .reveal table tr:hover td {
      background: rgba(255,255,255,0.03);
    }

    /* Staging visual */
    .stage-flow {
      display: flex;
      align-items: center;
      gap: 8px;
      margin: 0.5em 0;
      flex-wrap: wrap;
    }

    .stage-box {
      background: rgba(14,165,233,0.15);
      border: 1px solid rgba(14,165,233,0.3);
      border-radius: 12px;
      padding: 12px 20px;
      text-align: center;
      min-width: 100px;
      flex: 1;
    }

    .stage-box.active {
      background: rgba(14,165,233,0.3);
      border-color: var(--teal);
    }

    .stage-box .stage-num {
      font-size: 1.8em;
      font-weight: 900;
      color: var(--teal);
    }

    .stage-box .stage-desc {
      font-size: 0.6em;
      color: var(--slate);
      margin-top: 0.2em;
    }

    .stage-arrow {
      color: var(--teal);
      font-size: 1.2em;
    }

    /* Quiz styles */
    .quiz-container {
      background: rgba(139,92,246,0.05);
      border: 1px solid rgba(139,92,246,0.2);
      border-radius: 20px;
      padding: 30px;
      margin-top: 0.5em;
    }

    .quiz-question {
      font-size: 1em;
      font-weight: 600;
      margin-bottom: 1em;
      color: var(--white);
    }

    .quiz-options {
      display: grid;
      gap: 12px;
    }

    .quiz-option {
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.1);
      border-radius: 12px;
      padding: 14px 20px;
      cursor: pointer;
      transition: all 0.3s ease;
      font-size: 0.85em;
      display: flex;
      align-items: center;
      gap: 12px;
    }

    .quiz-option:hover {
      background: rgba(139,92,246,0.1);
      border-color: var(--purple);
    }

    .quiz-option.correct {
      background: rgba(16,185,129,0.2) !important;
      border-color: var(--emerald) !important;
    }

    .quiz-option.incorrect {
      background: rgba(244,63,94,0.15) !important;
      border-color: var(--rose) !important;
    }

    .quiz-option .option-letter {
      width: 30px;
      height: 30px;
      border-radius: 50%;
      background: rgba(255,255,255,0.1);
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.85em;
      flex-shrink: 0;
    }

    .quiz-feedback {
      margin-top: 1em;
      padding: 14px 20px;
      border-radius: 12px;
      font-size: 0.85em;
      display: none;
    }

    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct-fb {
      background: rgba(16,185,129,0.15);
      border: 1px solid var(--emerald);
      color: var(--emerald);
    }
    .quiz-feedback.incorrect-fb {
      background: rgba(244,63,94,0.1);
      border: 1px solid var(--rose);
      color: var(--rose);
    }

    /* Comparison highlight */
    .vs-container {
      display: grid;
      grid-template-columns: 1fr auto 1fr;
      gap: 20px;
      align-items: center;
      margin-top: 0.5em;
    }

    .vs-card {
      background: rgba(255,255,255,0.03);
      border: 1px solid rgba(255,255,255,0.1);
      border-radius: 16px;
      padding: 20px;
    }

    .vs-divider {
      font-size: 1.5em;
      font-weight: 900;
      color: var(--amber);
      text-align: center;
    }

    /* Timeline */
    .timeline {
      position: relative;
      margin: 1em 0;
      padding-left: 30px;
    }

    .timeline::before {
      content: '';
      position: absolute;
      left: 8px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: linear-gradient(to bottom, var(--teal), var(--purple));
    }

    .timeline-item {
      position: relative;
      margin-bottom: 1em;
      padding-left: 20px;
    }

    .timeline-item::before {
      content: '';
      position: absolute;
      left: -26px;
      top: 6px;
      width: 12px;
      height: 12px;
      border-radius: 50%;
      background: var(--teal);
      border: 2px solid var(--navy);
    }

    .timeline-item .timeline-title {
      font-weight: 700;
      color: var(--teal);
      font-size: 0.9em;
    }

    .timeline-item .timeline-desc {
      font-size: 0.75em;
      color: var(--slate);
    }

    /* Progress bar */
    .score-bar {
      width: 100%;
      height: 12px;
      background: rgba(255,255,255,0.1);
      border-radius: 6px;
      overflow: hidden;
      margin-top: 0.5em;
    }

    .score-bar-fill {
      height: 100%;
      border-radius: 6px;
      transition: width 1s ease;
    }

    .score-bar-fill.excellent { background: linear-gradient(90deg, var(--emerald), var(--teal)); }
    .score-bar-fill.good { background: linear-gradient(90deg, var(--amber), var(--emerald)); }
    .score-bar-fill.poor { background: linear-gradient(90deg, var(--rose), var(--amber)); }

    /* Image slides */
    .img-container {
      text-align: center;
      margin-top: 0.5em;
    }

    .img-container img {
      max-width: 90%;
      max-height: 55vh;
      border-radius: 12px;
      box-shadow: 0 8px 32px rgba(0,0,0,0.3);
    }

    /* Floating badge */
    .badge {
      position: absolute;
      top: 20px;
      right: 20px;
      background: rgba(14,165,233,0.15);
      border: 1px solid rgba(14,165,233,0.3);
      border-radius: 20px;
      padding: 6px 16px;
      font-size: 0.55em;
      color: var(--teal);
      font-weight: 600;
    }

    /* Key pearl icon */
    .key-icon { color: var(--amber); margin-right: 6px; }
    .danger-icon { color: var(--rose); margin-right: 6px; }

    /* Slide background gradient */
    .reveal .slides section[data-background-gradient] {
      color: var(--white);
    }

    /* Override reveal defaults */
    .reveal .slide-background { background: var(--navy); }
    .reveal .progress { height: 4px; }
    .reveal .progress span { background: linear-gradient(90deg, var(--teal), var(--purple)); }
    .reveal .controls .controls-arrow { color: var(--teal); }

    /* Fragment animations */
    .reveal .fragment.grow-in {
      opacity: 0;
      transform: scale(0.8);
      transition: all 0.5s ease;
    }
    .reveal .fragment.grow-in.visible {
      opacity: 1;
      transform: scale(1);
    }

    /* Small text helper */
    .small { font-size: 0.75em; }
    .tiny { font-size: 0.6em; color: var(--slate); }
    .center { text-align: center; }
    .highlight { color: var(--teal); font-weight: 700; }
    .highlight-amber { color: var(--amber); font-weight: 700; }
    .highlight-rose { color: var(--rose); font-weight: 700; }
    .highlight-emerald { color: var(--emerald); font-weight: 700; }

    /* Score tracker */
    #score-tracker {
      position: fixed;
      bottom: 60px;
      right: 20px;
      background: rgba(10,22,40,0.9);
      border: 1px solid rgba(139,92,246,0.3);
      border-radius: 12px;
      padding: 8px 16px;
      font-size: 14px;
      color: var(--purple);
      font-weight: 600;
      z-index: 100;
      display: none;
      backdrop-filter: blur(10px);
    }

    /* Responsive */
    @media (max-width: 768px) {
      .stat-grid, .two-col, .three-col { grid-template-columns: 1fr; }
      .vs-container { grid-template-columns: 1fr; }
      .reveal h1 { font-size: 1.8em; }
      .reveal .slides section { padding: 20px 30px; }
    }
  </style>
</head>
<body>
  <div id="score-tracker"><i class="fas fa-trophy"></i> Score: <span id="quiz-score">0</span>/<span id="quiz-total">0</span></div>

  <div class="reveal">
    <div class="slides">

      <!-- ============ TITLE SLIDE ============ -->
      <section class="title-slide" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <div style="margin-bottom: 0.5em;">
          <span class="tag tag-teal"><i class="fas fa-graduation-cap"></i> SURGICAL EDUCATION</span>
        </div>
        <h1>Pediatric Renal Masses</h1>
        <div class="subtitle">A Comprehensive Surgical Review</div>
        <div class="author">
          <strong>Mikael Petrosyan, MD, MBA, FACS, FAAP</strong>
          Division Chief, General &amp; Thoracic Surgery<br>
          Children's National Hospital | George Washington University<br>
          <span style="color:var(--teal)">Surgucation</span>
        </div>
        <div class="tiny" style="margin-top:2em; color:var(--slate);">
          <i class="fas fa-keyboard"></i> Use arrow keys or swipe to navigate &nbsp;|&nbsp;
          <i class="fas fa-expand"></i> Press F for fullscreen
        </div>
      </section>

      <!-- ============ LEARNING OBJECTIVES ============ -->
      <section>
        <h2><i class="fas fa-bullseye" style="color:var(--teal)"></i> Learning Objectives</h2>
        <ul>
          <li class="fragment">Classify pediatric renal masses by age, histology, and behavior</li>
          <li class="fragment">Apply COG and SIOP staging systems for Wilms tumor</li>
          <li class="fragment">Select appropriate surgical approach: radical nephrectomy vs. nephron-sparing surgery</li>
          <li class="fragment">Integrate molecular biomarkers into risk stratification and treatment planning</li>
          <li class="fragment">Differentiate Wilms tumor from RCC, CMN, clear cell sarcoma, and rhabdoid tumor</li>
          <li class="fragment">Recognize long-term sequelae and surveillance needs for survivors</li>
        </ul>
      </section>

      <!-- ============ THE BIG PICTURE ============ -->
      <section>
        <h2>Pediatric Renal Tumors: The Big Picture</h2>
        <div class="stat-grid">
          <div class="stat-card fragment">
            <div class="number">5%</div>
            <div class="label">of all childhood cancers</div>
          </div>
          <div class="stat-card fragment">
            <div class="number">500+</div>
            <div class="label">new cases/year in US</div>
          </div>
          <div class="stat-card fragment">
            <div class="number">>90%</div>
            <div class="label">5-year survival (WT)</div>
          </div>
        </div>
        <div class="info-box fragment" style="margin-top:1.5em">
          <i class="fas fa-lightbulb key-icon"></i>
          <strong>Key Concept:</strong> The "Big Three" pediatric renal tumors &mdash; Wilms Tumor, Congenital Mesoblastic Nephroma, and Renal Cell Carcinoma &mdash; differ fundamentally in age, biology, and management.
        </div>
      </section>

      <!-- ============ CLASSIFICATION OVERVIEW ============ -->
      <section>
        <h2>Classification by Age</h2>
        <div class="three-col">
          <div class="stat-card fragment" style="border-color: rgba(16,185,129,0.3)">
            <div style="font-size:2em; margin-bottom:0.2em"><i class="fas fa-baby" style="color:var(--emerald)"></i></div>
            <div style="font-weight:800; color:var(--emerald)">Infants (&lt;1 yr)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>CMN</strong> &mdash; #1 in neonates<br>
              Median: 1 month<br>
              <span class="tag tag-emerald">Classic</span>
              <span class="tag tag-emerald">Cellular</span>
              <span class="tag tag-emerald">Mixed</span>
            </div>
          </div>
          <div class="stat-card fragment" style="border-color: rgba(14,165,233,0.3)">
            <div style="font-size:2em; margin-bottom:0.2em"><i class="fas fa-child" style="color:var(--teal)"></i></div>
            <div style="font-weight:800; color:var(--teal)">Children (1&ndash;5 yrs)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>Wilms Tumor</strong> &mdash; 90%+ of renal tumors<br>
              Median: 3 years<br>
              <span class="tag tag-teal">Favorable</span>
              <span class="tag tag-rose">Anaplastic</span>
            </div>
          </div>
          <div class="stat-card fragment" style="border-color: rgba(139,92,246,0.3)">
            <div style="font-size:2em; margin-bottom:0.2em"><i class="fas fa-user" style="color:var(--purple)"></i></div>
            <div style="font-weight:800; color:var(--purple)">Adolescents (9&ndash;15 yrs)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>RCC</strong> &mdash; 2&ndash;6% of renal tumors<br>
              Mean: 9&ndash;15 years<br>
              <span class="tag tag-purple">MiT-RCC</span>
              <span class="tag tag-purple">Papillary</span>
            </div>
          </div>
        </div>
      </section>

      <!-- ============ INFOGRAPHIC: COMPARISON ============ -->
      <section>
        <h2>Clinical Comparison at a Glance</h2>
        <div class="img-container">
          <img src="assets/img/clinical-comparison.png" alt="Pediatric Renal Masses: A Comparative Guide to Wilms Tumor, RCC, and CMN">
        </div>
      </section>

      <!-- ============ SECTION: WILMS TUMOR ============ -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <div class="section-number">01</div>
        <span class="tag tag-teal" style="margin-bottom:0.5em">MOST COMMON PEDIATRIC RENAL TUMOR</span>
        <h2>Wilms Tumor<br><span style="font-size:0.5em; color:var(--slate)">Nephroblastoma</span></h2>
      </section>

      <!-- WT: Epidemiology -->
      <section>
        <h2>Wilms Tumor: Epidemiology</h2>
        <div class="badge"><i class="fas fa-chart-bar"></i> NCCN v2.2025</div>
        <div class="two-col">
          <div>
            <ul class="small">
              <li><span class="highlight">90%+</span> of renal tumors in patients &lt;20 years</li>
              <li>Incidence: <span class="highlight">5.7 per million</span> children</li>
              <li>~500&ndash;600 new US cases annually</li>
              <li>75%+ present between ages <strong>1&ndash;5 years</strong></li>
              <li>Median age: <strong>3 years</strong></li>
            </ul>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> <strong>Surgical Pearl:</strong> Unilateral median age 35mo (M) / 42mo (F). Bilateral presents earlier: 23mo (M) / 28.5mo (F).
            </div>
          </div>
          <div>
            <h3>Racial Disparities</h3>
            <div style="font-size:0.8em">
              <div style="display:flex; align-items:center; gap:10px; margin:0.3em 0">
                <div style="flex:1">African American</div>
                <div class="score-bar" style="flex:2"><div class="score-bar-fill excellent" style="width:85%"></div></div>
                <div style="color:var(--teal); font-weight:700">7.1/M</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.3em 0">
                <div style="flex:1">White</div>
                <div class="score-bar" style="flex:2"><div class="score-bar-fill excellent" style="width:68%"></div></div>
                <div style="color:var(--teal); font-weight:700">5.7/M</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.3em 0">
                <div style="flex:1">Asian</div>
                <div class="score-bar" style="flex:2"><div class="score-bar-fill excellent" style="width:52%"></div></div>
                <div style="color:var(--teal); font-weight:700">4.4/M</div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Genetics & Syndromes -->
      <section>
        <h2>Genetic Predisposition</h2>
        <p class="small" style="color:var(--slate)">Present in <span class="highlight">10&ndash;33%</span> of Wilms tumor cases</p>
        <div class="two-col">
          <div>
            <h3><i class="fas fa-exclamation-triangle" style="color:var(--rose)"></i> High-Risk Syndromes</h3>
            <table>
              <thead><tr><th>Syndrome</th><th>WT Risk</th><th>Features</th></tr></thead>
              <tbody>
                <tr class="fragment"><td><strong>WAGR</strong></td><td class="highlight-rose">45&ndash;60%</td><td><small>Wilms, Aniridia, GU abnormalities, intellectual disability</small></td></tr>
                <tr class="fragment"><td><strong>Denys-Drash</strong></td><td class="highlight-rose">~90%</td><td><small>DSD, mesangial sclerosis, renal failure</small></td></tr>
                <tr class="fragment"><td><strong>Perlman</strong></td><td class="highlight-rose">High</td><td><small>Overgrowth, organomegaly, characteristic facies</small></td></tr>
              </tbody>
            </table>
          </div>
          <div>
            <h3><i class="fas fa-exclamation-circle" style="color:var(--amber)"></i> Moderate-Risk</h3>
            <table>
              <thead><tr><th>Syndrome</th><th>Features</th></tr></thead>
              <tbody>
                <tr class="fragment"><td><strong>Beckwith-Wiedemann</strong></td><td><small>Macroglossia, hemihyperplasia, gigantism (~5% of WT)</small></td></tr>
                <tr class="fragment"><td><strong>Frasier</strong></td><td><small>GU abnormalities, FSGS</small></td></tr>
                <tr class="fragment"><td><strong>Li-Fraumeni</strong></td><td><small>TP53 mutations, multiple cancers</small></td></tr>
              </tbody>
            </table>
          </div>
        </div>
        <div class="warning-box fragment">
          <i class="fas fa-stethoscope danger-icon"></i> <strong>Screening Protocol:</strong> Physical exam + renal ultrasound <strong>every 3 months until age 7</strong> for all high-risk syndromes. Rationale: 90&ndash;98% of tumors occur by age 7.
        </div>
      </section>

      <!-- WT: Molecular Biology -->
      <section>
        <h2>Molecular Biology of Wilms Tumor</h2>
        <div class="two-col">
          <div>
            <h3>Key Genetic Loci</h3>
            <div class="timeline">
              <div class="timeline-item fragment">
                <div class="timeline-title">WT1 (11p13)</div>
                <div class="timeline-desc">Tumor suppressor gene; mutated in WAGR and Denys-Drash. Involved in kidney/gonad development.</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">WT2 / 11p15 (IGF2)</div>
                <div class="timeline-desc">Imprinting center; LOH or LOI at 11p15 associated with Beckwith-Wiedemann. IGF2 overexpression.</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">CTNNB1 (&beta;-catenin)</div>
                <div class="timeline-desc">Wnt pathway activating mutations; often co-occurs with WT1 mutations.</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">WTX (AMER1) at Xq11.1</div>
                <div class="timeline-desc">Deleted/mutated in ~30% of WT; Wnt pathway regulator.</div>
              </div>
            </div>
          </div>
          <div>
            <h3>Prognostic Biomarkers</h3>
            <div class="info-box fragment">
              <strong style="color:var(--rose)">Unfavorable Markers:</strong>
              <ul class="small" style="margin-top:0.3em">
                <li><strong>1q gain</strong> &mdash; Most powerful adverse marker</li>
                <li><strong>Combined LOH 1p + 16q</strong> &mdash; Increased relapse risk</li>
                <li><strong>11p15 LOH/LOI</strong> &mdash; Fewer data, under investigation</li>
              </ul>
            </div>
            <div class="info-box fragment">
              <strong style="color:var(--emerald)">Clinical Impact:</strong>
              <ul class="small" style="margin-top:0.3em">
                <li>Used to <span class="highlight">intensify treatment</span> in Stage I/II FHWT</li>
                <li>COG AREN trials: 1q gain + LOH 1p/16q &rarr; upgrade to DD4A or Regimen M</li>
                <li>SIOP: Blastemal type after chemo = high risk</li>
              </ul>
            </div>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> <strong>Key:</strong> TP53 mutations are hallmark of anaplastic histology and predict chemoresistance.
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Presentation -->
      <section>
        <h2>Clinical Presentation</h2>
        <div class="two-col">
          <div>
            <h3>Wilms Tumor</h3>
            <div style="font-size:0.85em">
              <div style="display:flex; align-items:center; gap:10px; margin:0.5em 0" class="fragment">
                <div style="color:var(--teal); font-weight:900; font-size:1.3em; width:50px">83%</div>
                <div>Abdominal mass/distention</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.5em 0" class="fragment">
                <div style="color:var(--teal); font-weight:900; font-size:1.3em; width:50px">37%</div>
                <div>Abdominal pain</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.5em 0" class="fragment">
                <div style="color:var(--teal); font-weight:900; font-size:1.3em; width:50px">23%</div>
                <div>Fever</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.5em 0" class="fragment">
                <div style="color:var(--teal); font-weight:900; font-size:1.3em; width:50px">25%</div>
                <div>Hematuria</div>
              </div>
              <div style="display:flex; align-items:center; gap:10px; margin:0.5em 0" class="fragment">
                <div style="color:var(--teal); font-weight:900; font-size:1.3em; width:50px">25%</div>
                <div>Hypertension</div>
              </div>
            </div>
          </div>
          <div>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> <strong>Classic Scenario:</strong> A <span class="highlight-amber">healthy-appearing child</span> with an incidentally discovered, firm, smooth, non-tender abdominal mass &mdash; found during bathing or dressing.
            </div>
            <div class="warning-box fragment">
              <i class="fas fa-exchange-alt danger-icon"></i> <strong>WT vs Neuroblastoma:</strong><br>
              <table class="small" style="margin-top:0.5em">
                <tr><td></td><td><strong>Wilms</strong></td><td><strong>Neuroblastoma</strong></td></tr>
                <tr><td>Appearance</td><td class="highlight-emerald">Healthy</td><td class="highlight-rose">Ill-appearing</td></tr>
                <tr><td>Calcification</td><td>5&ndash;10%</td><td>60&ndash;70%</td></tr>
                <tr><td>Mass origin</td><td>Intrarenal</td><td>Adrenal/paraspinal</td></tr>
                <tr><td>Crosses midline</td><td>Rare</td><td>Common</td></tr>
              </table>
            </div>
            <div class="info-box fragment">
              <i class="fas fa-info-circle" style="color:var(--teal)"></i> ~10% have <strong>acquired von Willebrand disease</strong> (coagulopathy) &mdash; check coag studies!
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Imaging -->
      <section>
        <h2>Diagnostic Imaging</h2>
        <div class="two-col">
          <div>
            <h3>Initial Workup</h3>
            <ul class="small">
              <li class="fragment"><strong>Abdominal ultrasound</strong> &mdash; first-line</li>
              <li class="fragment"><strong>CT abdomen/pelvis with contrast</strong> or MRI</li>
              <li class="fragment"><strong>Chest CT</strong> &mdash; lung metastasis screening</li>
              <li class="fragment"><strong>Urine catecholamines</strong> (HVA/VMA) &mdash; rule out neuroblastoma</li>
            </ul>
            <h3 class="fragment" style="margin-top:1em">Lab Studies</h3>
            <ul class="small">
              <li class="fragment">CBC with differential</li>
              <li class="fragment">CMP, urinalysis</li>
              <li class="fragment">Coagulation studies (PT/PTT)</li>
              <li class="fragment">Screen for predisposition syndromes</li>
            </ul>
          </div>
          <div>
            <h3>Imaging Characteristics</h3>
            <div class="info-box fragment">
              <strong>Wilms Tumor:</strong>
              <ul class="small">
                <li>Large, well-circumscribed intrarenal mass</li>
                <li>Heterogeneous enhancement</li>
                <li><span class="highlight">"Claw sign"</span> &mdash; normal renal parenchyma wrapping around tumor</li>
                <li>Minimal calcification (5&ndash;10%)</li>
                <li>Check for renal vein/IVC tumor thrombus</li>
              </ul>
            </div>
            <div class="info-box fragment">
              <strong>CMN on MRI:</strong>
              <ul class="small">
                <li>Classic: Homogeneous, <span class="highlight">"concentric ring sign"</span> (58%)</li>
                <li>T2-isointense, T1-hypointense</li>
                <li>Cellular type: more heterogeneous, larger</li>
              </ul>
            </div>
          </div>
        </div>
      </section>

      <!-- WT: COG Staging -->
      <section>
        <h2>COG Staging System</h2>
        <div class="badge">Children's Oncology Group</div>
        <div class="stage-flow">
          <div class="stage-box fragment">
            <div class="stage-num">I</div>
            <div class="stage-desc">Limited to kidney<br>Completely resected<br>Capsule intact</div>
          </div>
          <div class="stage-arrow fragment"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box fragment">
            <div class="stage-num">II</div>
            <div class="stage-desc">Extends beyond kidney<br>Completely resected<br>No residual tumor</div>
          </div>
          <div class="stage-arrow fragment"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box fragment">
            <div class="stage-num">III</div>
            <div class="stage-desc">Residual tumor<br>in abdomen<br>LN+, spillage, biopsy</div>
          </div>
          <div class="stage-arrow fragment"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box fragment">
            <div class="stage-num">IV</div>
            <div class="stage-desc">Hematogenous<br>metastases<br>Lung, liver, bone, brain</div>
          </div>
          <div class="stage-arrow fragment"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box fragment" style="border-color: var(--amber)">
            <div class="stage-num" style="color:var(--amber)">V</div>
            <div class="stage-desc">Bilateral renal<br>involvement<br>at diagnosis</div>
          </div>
        </div>
        <div class="warning-box fragment" style="margin-top:1em">
          <i class="fas fa-exclamation-triangle danger-icon"></i> <strong>Stage III triggers include:</strong> LN involvement, peritoneal implants, tumor spillage, biopsy before removal, tumor removed in &gt;1 piece, positive margins.
        </div>
      </section>

      <!-- WT: COG vs SIOP -->
      <section>
        <h2>COG vs. SIOP: Two Philosophies</h2>
        <div class="vs-container">
          <div class="vs-card fragment">
            <h3 style="text-align:center"><i class="fas fa-flag-usa" style="color:var(--teal)"></i> COG (North America)</h3>
            <ul class="small">
              <li><strong>Upfront surgery</strong> &rarr; then chemotherapy</li>
              <li>Staging based on surgical/pathologic findings</li>
              <li>Allows complete histologic assessment</li>
              <li>Identifies anaplasia pre-chemo</li>
              <li>Risk: more surgical complications (14.6% tumor rupture)</li>
            </ul>
          </div>
          <div class="vs-divider fragment">VS</div>
          <div class="vs-card fragment">
            <h3 style="text-align:center"><i class="fas fa-globe-europe" style="color:var(--purple)"></i> SIOP (Europe/International)</h3>
            <ul class="small">
              <li><strong>Neoadjuvant chemotherapy</strong> &rarr; then surgery</li>
              <li>Staging after preoperative treatment</li>
              <li>Tumor shrinkage &rarr; easier resection</li>
              <li>0% tumor rupture rate</li>
              <li>Risk: may alter histology, miss anaplasia</li>
            </ul>
          </div>
        </div>
        <div class="info-box fragment" style="margin-top:1em">
          <i class="fas fa-equals" style="color:var(--teal)"></i> <strong>Bottom Line:</strong> Both approaches yield comparable overall survival (&gt;90% for favorable histology). The debate continues, but outcomes are equally excellent.
        </div>
      </section>

      <!-- WT: Histology -->
      <section>
        <h2>Histologic Classification</h2>
        <div class="two-col">
          <div>
            <h3 class="highlight-emerald"><i class="fas fa-check-circle"></i> Favorable Histology (FHWT)</h3>
            <ul class="small">
              <li class="fragment"><strong>Triphasic pattern:</strong> blastemal + epithelial + stromal</li>
              <li class="fragment">Can be biphasic or monophasic</li>
              <li class="fragment">No anaplastic features</li>
              <li class="fragment"><span class="highlight-emerald">5-year OS: &gt;90%</span></li>
            </ul>
            <div class="info-box fragment" style="margin-top:1em">
              <strong>SIOP Risk Groups (post-chemo):</strong><br>
              <span class="tag tag-emerald">Low</span> Completely necrotic<br>
              <span class="tag tag-teal">Intermediate</span> Epithelial, stromal, mixed, regressive<br>
              <span class="tag tag-rose">High</span> Blastemal predominant, diffuse anaplasia
            </div>
          </div>
          <div>
            <h3 class="highlight-rose"><i class="fas fa-exclamation-circle"></i> Anaplastic Histology</h3>
            <div class="warning-box fragment">
              <strong>Focal Anaplasia:</strong>
              <ul class="small">
                <li>Defined focus within primary tumor</li>
                <li>Confined to renal parenchyma</li>
                <li>1&ndash;2 foci, &lt;15mm each</li>
                <li>Not in vascular spaces</li>
                <li>Better prognosis with appropriate therapy</li>
              </ul>
            </div>
            <div class="warning-box fragment">
              <strong>Diffuse Anaplasia:</strong>
              <ul class="small">
                <li>Multifocal / non-localized</li>
                <li>Beyond tumor capsule</li>
                <li>In vessels, extrarenal sites, or metastases</li>
                <li><span class="highlight-rose">Stage IV: 29&ndash;45% 5-year OS</span></li>
                <li>Associated with <strong>TP53 mutations</strong></li>
              </ul>
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Treatment Regimens -->
      <section>
        <h2>COG Chemotherapy Regimens</h2>
        <table>
          <thead>
            <tr><th>Regimen</th><th>Risk Level</th><th>Agents</th><th>Duration</th></tr>
          </thead>
          <tbody>
            <tr class="fragment">
              <td><strong>EE4A</strong></td>
              <td><span class="tag tag-emerald">Very Low / Low</span></td>
              <td>Vincristine + Dactinomycin</td>
              <td>18 weeks</td>
            </tr>
            <tr class="fragment">
              <td><strong>DD4A</strong></td>
              <td><span class="tag tag-teal">Standard</span></td>
              <td>Vincristine + Dactinomycin + <span class="highlight-amber">Doxorubicin</span></td>
              <td>24 weeks</td>
            </tr>
            <tr class="fragment">
              <td><strong>Regimen M</strong></td>
              <td><span class="tag tag-amber">Higher Risk</span></td>
              <td>VCR + Dact + Doxo + Cyclophosphamide + Etoposide</td>
              <td>24 weeks</td>
            </tr>
            <tr class="fragment">
              <td><strong>Regimen I</strong></td>
              <td><span class="tag tag-rose">Blastemal</span></td>
              <td>VCR + Doxo + Cyclo + Etoposide (high-dose)</td>
              <td>24 weeks</td>
            </tr>
            <tr class="fragment">
              <td><strong>UH-1</strong></td>
              <td><span class="tag tag-rose">Stage IV FA</span></td>
              <td>VCR + Doxo + Cyclo + Carboplatin + Etoposide</td>
              <td>Intensive</td>
            </tr>
            <tr class="fragment">
              <td><strong>UH-2</strong></td>
              <td><span class="tag tag-rose">Stage II&ndash;IV DA</span></td>
              <td>VCR + Doxo + Cyclo + Carbo + Etop + <strong>Irinotecan</strong></td>
              <td>Most toxic</td>
            </tr>
          </tbody>
        </table>
        <div class="pearl-box fragment" style="margin-top:0.5em">
          <i class="fas fa-gem key-icon"></i> <strong>Doxorubicin:</strong> Cumulative dose in DD4A = 150 mg/m&sup2;. Monitor echocardiogram &mdash; younger children and females more susceptible to cardiotoxicity.
        </div>
      </section>

      <!-- WT: Radiation -->
      <section>
        <h2>Radiation Therapy</h2>
        <div class="two-col">
          <div>
            <h3>Indications</h3>
            <ul class="small">
              <li class="fragment"><strong>Stage III FHWT:</strong> Flank or whole-abdomen radiation</li>
              <li class="fragment"><strong>Stage IV:</strong> Whole-lung radiation for pulmonary metastases</li>
              <li class="fragment"><strong>Anaplastic tumors:</strong> Higher doses for Stage III DA</li>
            </ul>
            <div class="info-box fragment" style="margin-top:1em">
              <strong>Timing:</strong> RT to primary site typically <span class="highlight">10&ndash;14 days post-surgery</span>. Coordinate with chemotherapy to avoid co-administration with full-dose dactinomycin or doxorubicin.
            </div>
          </div>
          <div>
            <h3>NOT Indicated</h3>
            <ul class="small">
              <li class="fragment">Stage I&ndash;II Favorable Histology</li>
              <li class="fragment">Stage I Anaplastic (focal)</li>
              <li class="fragment">Low-risk completely necrotic tumors</li>
            </ul>
            <div class="pearl-box fragment" style="margin-top:1em">
              <i class="fas fa-gem key-icon"></i> Goal of modern protocols: <strong>de-escalate radiation</strong> whenever possible to minimize late effects (second malignancies, growth impairment, cardiac toxicity).
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Surgery -->
      <section>
        <h2>Surgical Management</h2>
        <div class="two-col">
          <div>
            <h3><i class="fas fa-cut" style="color:var(--teal)"></i> Radical Nephrectomy</h3>
            <div class="timeline">
              <div class="timeline-item fragment">
                <div class="timeline-title">1. Transabdominal approach</div>
                <div class="timeline-desc">Preferred over flank (OR 5.3&times; complication risk with flank incision)</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">2. Explore &amp; biopsy</div>
                <div class="timeline-desc">Liver, peritoneal surfaces, contralateral kidney</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">3. Assess vessels</div>
                <div class="timeline-desc">Evaluate renal vein/IVC for tumor thrombus</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">4. Lymph node sampling</div>
                <div class="timeline-desc"><strong>Minimum 5 nodes</strong> from hilum, pericaval, para-aortic</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">5. En bloc nephrectomy</div>
                <div class="timeline-desc">Avoid tumor spillage. Adrenalectomy NOT required if uninvolved.</div>
              </div>
            </div>
          </div>
          <div>
            <h3><i class="fas fa-hand-holding-medical" style="color:var(--emerald)"></i> Nephron-Sparing Surgery</h3>
            <div class="info-box fragment">
              <strong>Indications for NSS:</strong>
              <ul class="small">
                <li>Bilateral tumors (Stage V)</li>
                <li>Solitary kidney</li>
                <li>Predisposing syndromes</li>
                <li>High risk for CKD</li>
              </ul>
            </div>
            <div class="info-box fragment">
              <strong>Favorable Imaging for NSS:</strong>
              <ul class="small">
                <li>Peripheral/polar location</li>
                <li>Preserves &ge;1/3 normal kidney</li>
                <li>No hilar/sinus invasion</li>
                <li>Clear tumor&ndash;parenchyma interface</li>
              </ul>
            </div>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> NSS protocol: Neoadjuvant chemo 6&ndash;12 weeks &rarr; re-image at week 6 &rarr; surgery within 12 weeks of starting chemo.
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Complications -->
      <section>
        <h2>Surgical Complications</h2>
        <div class="two-col">
          <div>
            <h3>Perioperative (NWTS-4)</h3>
            <p class="small" style="color:var(--slate)">Overall rate: 12.7% (down from 19.8% in NWTS-3)</p>
            <table>
              <thead><tr><th>Complication</th><th>Rate</th></tr></thead>
              <tbody>
                <tr class="fragment"><td>Intestinal obstruction</td><td><strong>5.1%</strong> (most common)</td></tr>
                <tr class="fragment"><td>Extensive hemorrhage</td><td>1.9%</td></tr>
                <tr class="fragment"><td>Wound infection</td><td>1.9%</td></tr>
                <tr class="fragment"><td>Vascular injury</td><td>1.5%</td></tr>
              </tbody>
            </table>
          </div>
          <div>
            <h3>Risk Factors</h3>
            <div class="warning-box fragment">
              <strong>Major Risk Factors:</strong>
              <ul class="small">
                <li><strong>General surgeon</strong> performing nephrectomy: <span class="highlight-rose">OR 9.0&times;</span> vs pediatric surgeon</li>
                <li>IVC extension: OR 3.8</li>
                <li>Flank/paramedian incision: OR 5.3</li>
                <li>Tumor &ge;10 cm: OR 2.0</li>
              </ul>
            </div>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> Preoperative chemo reduces surgical complications &mdash; <strong>0% tumor rupture</strong> vs 14.6% with immediate nephrectomy.
            </div>
          </div>
        </div>
      </section>

      <!-- WT: Outcomes -->
      <section>
        <h2>Outcomes by Stage &amp; Histology</h2>
        <div class="two-col">
          <div>
            <h3>Favorable Histology (5-yr OS)</h3>
            <div style="font-size:0.85em">
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Stage I</span><span class="highlight-emerald">96&ndash;97%</span></div>
                <div class="score-bar"><div class="score-bar-fill excellent" style="width:97%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Stage II</span><span class="highlight-emerald">93&ndash;94%</span></div>
                <div class="score-bar"><div class="score-bar-fill excellent" style="width:94%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Stage III</span><span class="highlight-amber">85&ndash;92%</span></div>
                <div class="score-bar"><div class="score-bar-fill good" style="width:89%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Stage IV</span><span class="highlight-amber">84&ndash;89%</span></div>
                <div class="score-bar"><div class="score-bar-fill good" style="width:87%"></div></div>
              </div>
            </div>
          </div>
          <div>
            <h3>By Histology Risk</h3>
            <div style="font-size:0.85em">
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Low risk (necrotic/epithelial/stromal)</span><span class="highlight-emerald">97&ndash;100%</span></div>
                <div class="score-bar"><div class="score-bar-fill excellent" style="width:99%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Intermediate (FHWT)</span><span class="highlight-emerald">95%</span></div>
                <div class="score-bar"><div class="score-bar-fill excellent" style="width:95%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>High risk (blastemal/anaplastic)</span><span class="highlight-rose">75%</span></div>
                <div class="score-bar"><div class="score-bar-fill poor" style="width:75%"></div></div>
              </div>
              <div class="fragment" style="margin:0.4em 0">
                <div style="display:flex;justify-content:space-between"><span>Stage IV Diffuse Anaplasia</span><span class="highlight-rose">29&ndash;45%</span></div>
                <div class="score-bar"><div class="score-bar-fill poor" style="width:37%"></div></div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <!-- ============ QUIZ 1 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #1</h2>
        <div class="quiz-container" id="quiz1">
          <div class="quiz-question">A 3-year-old healthy-appearing girl is found to have a firm, non-tender abdominal mass during a bath. CT shows a large intrarenal mass with a "claw sign" and no calcification. What is the most likely diagnosis?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz1')">
              <div class="option-letter">A</div>
              <div>Neuroblastoma</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz1')">
              <div class="option-letter">B</div>
              <div>Wilms tumor</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz1')">
              <div class="option-letter">C</div>
              <div>Congenital mesoblastic nephroma</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz1')">
              <div class="option-letter">D</div>
              <div>Renal cell carcinoma</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz1-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 2 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #2</h2>
        <div class="quiz-container" id="quiz2">
          <div class="quiz-question">A Wilms tumor is biopsied prior to removal. The tumor is otherwise limited to the kidney with no lymph node involvement. What is the COG stage?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz2')">
              <div class="option-letter">A</div>
              <div>Stage I</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz2')">
              <div class="option-letter">B</div>
              <div>Stage II</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz2')">
              <div class="option-letter">C</div>
              <div>Stage III</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz2')">
              <div class="option-letter">D</div>
              <div>Stage IV</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz2-feedback"></div>
        </div>
      </section>

      <!-- ============ SECTION: OTHER TUMORS ============ -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <div class="section-number">02</div>
        <span class="tag tag-emerald">NEONATAL TUMORS &amp; RARE VARIANTS</span>
        <h2>Beyond Wilms Tumor</h2>
      </section>

      <!-- CMN -->
      <section>
        <h2>Congenital Mesoblastic Nephroma</h2>
        <div class="badge"><i class="fas fa-baby"></i> #1 in Neonates</div>
        <div class="two-col">
          <div>
            <h3>Epidemiology</h3>
            <ul class="small">
              <li>3&ndash;10% of pediatric renal tumors</li>
              <li><strong>Most common renal tumor in infants &lt;3 months</strong></li>
              <li>90% diagnosed within first year of life</li>
              <li>Median age: <span class="highlight">1 month</span></li>
              <li>Male predominance 2:1</li>
              <li>10&ndash;15% diagnosed prenatally</li>
            </ul>
            <h3 style="margin-top:0.8em">Subtypes</h3>
            <div class="three-col" style="gap:10px; font-size:0.8em">
              <div class="stat-card fragment" style="padding:12px">
                <div style="font-weight:800; color:var(--emerald)">Classic</div>
                <div class="tiny">45%</div>
                <div class="tiny">EGFR ITD</div>
                <div class="tiny highlight-emerald">0% recurrence</div>
              </div>
              <div class="stat-card fragment" style="padding:12px">
                <div style="font-weight:800; color:var(--amber)">Cellular</div>
                <div class="tiny">21%</div>
                <div class="tiny">ETV6-NTRK3 fusion</div>
                <div class="tiny highlight-amber">Higher recurrence</div>
              </div>
              <div class="stat-card fragment" style="padding:12px">
                <div style="font-weight:800; color:var(--purple)">Mixed</div>
                <div class="tiny">29%</div>
                <div class="tiny">EGFR ITD</div>
                <div class="tiny highlight-amber">Variable</div>
              </div>
            </div>
          </div>
          <div>
            <h3>Treatment</h3>
            <div class="info-box fragment">
              <strong>Surgery is curative:</strong> Complete nephrectomy is usually sufficient. <span class="highlight-emerald">96&ndash;100% survival.</span>
            </div>
            <div class="info-box fragment">
              <strong>Chemo considerations:</strong>
              <ul class="small">
                <li>NOT routine for classic CMN</li>
                <li>Consider for cellular variant in patients &gt;3 months</li>
                <li>Tumor spillage / positive margins</li>
                <li>Stage II&ndash;III cellular or mixed</li>
                <li>Recurrent or metastatic disease</li>
              </ul>
            </div>
            <div class="pearl-box fragment">
              <i class="fas fa-gem key-icon"></i> <strong>New Targeted Therapy:</strong> ETV6-NTRK3 fusion makes cellular CMN susceptible to <span class="highlight">TRK inhibitors</span> (larotrectinib, entrectinib) for advanced/recurrent cases.
            </div>
          </div>
        </div>
      </section>

      <!-- RCC -->
      <section>
        <h2>Pediatric Renal Cell Carcinoma</h2>
        <div class="two-col">
          <div>
            <h3>Key Differences from Adult RCC</h3>
            <ul class="small">
              <li class="fragment">2&ndash;6% of pediatric renal tumors</li>
              <li class="fragment">Mean age: <span class="highlight">9&ndash;15 years</span></li>
              <li class="fragment">Incidence increasing: +3.7%/year in children</li>
              <li class="fragment">20% present with metastases at diagnosis</li>
            </ul>
            <h3 style="margin-top:0.8em">Histology: Pediatric vs Adult</h3>
            <table class="fragment">
              <thead><tr><th>Subtype</th><th>Pediatric</th><th>Adult</th></tr></thead>
              <tbody>
                <tr><td><strong>MiT-RCC (TFE3/TFEB)</strong></td><td class="highlight">36&ndash;56%</td><td>Rare</td></tr>
                <tr><td><strong>Papillary</strong></td><td>20&ndash;30%</td><td>~15%</td></tr>
                <tr><td><strong>Clear cell</strong></td><td>6&ndash;23%</td><td class="highlight-rose">~70%</td></tr>
              </tbody>
            </table>
          </div>
          <div>
            <h3>Treatment</h3>
            <div class="info-box fragment">
              <strong>Surgery is the cornerstone:</strong> Complete resection is curative for localized disease. Even N1M0 does well without adjuvant therapy (87.1% 4-yr OS).
            </div>
            <div class="info-box fragment">
              <strong>Metastatic/Unresectable:</strong><br>
              <span class="highlight">Sunitinib</span> (TKI) per SIOP-RTSG UMBRELLA protocol<br>
              Other options: axitinib, cabozantinib, nivolumab
            </div>
            <h3 style="margin-top:0.8em">Outcomes</h3>
            <div style="font-size:0.8em" class="fragment">
              <div style="display:flex;justify-content:space-between"><span>Localized</span><span class="highlight-emerald">96.8%</span></div>
              <div class="score-bar"><div class="score-bar-fill excellent" style="width:97%"></div></div>
              <div style="display:flex;justify-content:space-between; margin-top:0.3em"><span>Metastatic</span><span class="highlight-rose">45.6%</span></div>
              <div class="score-bar"><div class="score-bar-fill poor" style="width:46%"></div></div>
            </div>
          </div>
        </div>
      </section>

      <!-- Clear Cell Sarcoma & Rhabdoid Tumor -->
      <section>
        <h2>Rare but Critical Tumors</h2>
        <div class="two-col">
          <div>
            <h3 style="color:var(--amber)"><i class="fas fa-bone"></i> Clear Cell Sarcoma (CCSK)</h3>
            <ul class="small">
              <li class="fragment"><strong>BCOR</strong> internal tandem duplications (85% of cases)</li>
              <li class="fragment">Known as the <span class="highlight-amber">"bone-metastasizing renal tumor"</span></li>
              <li class="fragment">23% develop bone metastases (spine, pelvis, ribs)</li>
              <li class="fragment">Must get <strong>bone scan</strong> (unlike Wilms)</li>
              <li class="fragment">Requires more intensive chemo + radiation</li>
              <li class="fragment">Imaging can mimic Wilms &mdash; differentiation requires pathology</li>
            </ul>
          </div>
          <div>
            <h3 style="color:var(--rose)"><i class="fas fa-brain"></i> Rhabdoid Tumor (MRTK)</h3>
            <ul class="small">
              <li class="fragment"><strong>SMARCB1/INI1</strong> loss (chromosome 22q11.2)</li>
              <li class="fragment">Median age: <span class="highlight-rose">&lt;1 year</span></li>
              <li class="fragment">Most aggressive pediatric renal tumor</li>
              <li class="fragment"><span class="highlight-rose">~25% have synchronous brain tumors</span> (AT/RT)</li>
              <li class="fragment">Must get <strong>brain MRI</strong> at diagnosis</li>
              <li class="fragment">Poor prognosis despite aggressive multimodal therapy</li>
            </ul>
          </div>
        </div>
        <div class="warning-box fragment" style="margin-top:0.8em">
          <i class="fas fa-exclamation-triangle danger-icon"></i> <strong>Critical Teaching Point:</strong> Any renal tumor in an infant &lt;6 months with aggressive features &rarr; think rhabdoid. Any renal tumor with bone mets &rarr; think clear cell sarcoma. Both require specific additional imaging and more aggressive protocols than standard Wilms.
        </div>
      </section>

      <!-- Nephrogenic Rests -->
      <section>
        <h2>Nephrogenic Rests</h2>
        <p class="small" style="color:var(--slate)">Precursor lesions found in ~1% of infant autopsies and 35&ndash;40% of Wilms tumor specimens</p>
        <div class="two-col">
          <div>
            <div class="stat-card fragment">
              <h3 style="color:var(--teal)">Perilobar Rests (PLNR)</h3>
              <ul class="small">
                <li>Located at kidney periphery</li>
                <li>Associated with <strong>Beckwith-Wiedemann</strong></li>
                <li>11p15 LOH/LOI</li>
                <li>Tend to be multifocal &rarr; <strong>nephroblastomatosis</strong></li>
                <li>Higher risk of bilateral/metachronous WT</li>
              </ul>
            </div>
          </div>
          <div>
            <div class="stat-card fragment">
              <h3 style="color:var(--purple)">Intralobar Rests (ILNR)</h3>
              <ul class="small">
                <li>Located anywhere within renal lobe</li>
                <li>Associated with <strong>WAGR, Denys-Drash</strong></li>
                <li>WT1 mutations</li>
                <li>Often solitary</li>
                <li>Earlier age of WT development</li>
              </ul>
            </div>
          </div>
        </div>
        <div class="info-box fragment" style="margin-top:0.8em">
          <i class="fas fa-eye" style="color:var(--teal)"></i> <strong>Management:</strong> Nephroblastomatosis (diffuse/multifocal rests) &rarr; chemotherapy to prevent malignant transformation. Close surveillance with serial imaging for isolated rests.
        </div>
      </section>

      <!-- ============ QUIZ 3 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #3</h2>
        <div class="quiz-container" id="quiz3">
          <div class="quiz-question">A 2-month-old boy presents with a palpable abdominal mass. Ultrasound reveals a solid renal tumor. What is the most likely diagnosis?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz3')">
              <div class="option-letter">A</div>
              <div>Wilms tumor</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz3')">
              <div class="option-letter">B</div>
              <div>Renal cell carcinoma</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz3')">
              <div class="option-letter">C</div>
              <div>Congenital mesoblastic nephroma</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz3')">
              <div class="option-letter">D</div>
              <div>Clear cell sarcoma</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz3-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 4 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #4</h2>
        <div class="quiz-container" id="quiz4">
          <div class="quiz-question">A child with a renal mass is found to have bone metastases. Which renal tumor is most associated with osseous spread?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz4')">
              <div class="option-letter">A</div>
              <div>Wilms tumor (favorable histology)</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz4')">
              <div class="option-letter">B</div>
              <div>Clear cell sarcoma of the kidney</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz4')">
              <div class="option-letter">C</div>
              <div>Congenital mesoblastic nephroma</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz4')">
              <div class="option-letter">D</div>
              <div>Renal cell carcinoma</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz4-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 5 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #5</h2>
        <div class="quiz-container" id="quiz5">
          <div class="quiz-question">Which molecular alteration is characteristically associated with rhabdoid tumor of the kidney?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz5')">
              <div class="option-letter">A</div>
              <div>WT1 mutation</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz5')">
              <div class="option-letter">B</div>
              <div>BCOR internal tandem duplication</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz5')">
              <div class="option-letter">C</div>
              <div>SMARCB1/INI1 loss</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz5')">
              <div class="option-letter">D</div>
              <div>ETV6-NTRK3 fusion</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz5-feedback"></div>
        </div>
      </section>

      <!-- ============ SECTION: LONG TERM ============ -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <div class="section-number">03</div>
        <span class="tag tag-amber">SURVIVORSHIP</span>
        <h2>Long-Term Outcomes<br>&amp; Late Effects</h2>
      </section>

      <!-- Late Effects -->
      <section>
        <h2>Late Effects of Multimodal Therapy</h2>
        <div class="three-col" style="font-size:0.8em">
          <div>
            <h3 style="color:var(--teal)"><i class="fas fa-pills"></i> Chemotherapy</h3>
            <div class="stat-card fragment" style="text-align:left; padding:14px">
              <strong>Doxorubicin:</strong>
              <ul class="small">
                <li>Dose-dependent cardiotoxicity</li>
                <li>Echo monitoring required</li>
                <li>Young age &amp; female = higher risk</li>
              </ul>
            </div>
            <div class="stat-card fragment" style="text-align:left; padding:14px; margin-top:10px">
              <strong>Cyclophosphamide:</strong>
              <ul class="small">
                <li>Gonadal toxicity (&gt;4 g/m&sup2;)</li>
                <li>Oligospermia/azoospermia</li>
                <li>Bladder malignancy risk</li>
                <li><span class="highlight-amber">Fertility counseling mandatory</span></li>
              </ul>
            </div>
          </div>
          <div>
            <h3 style="color:var(--amber)"><i class="fas fa-radiation"></i> Radiation</h3>
            <div class="stat-card fragment" style="text-align:left; padding:14px">
              <strong>Abdominal:</strong>
              <ul class="small">
                <li>Bowel obstruction</li>
                <li>Diabetes mellitus</li>
                <li>Colorectal cancer</li>
                <li>Hepatic toxicity</li>
              </ul>
            </div>
            <div class="stat-card fragment" style="text-align:left; padding:14px; margin-top:10px">
              <strong>Pelvic:</strong>
              <ul class="small">
                <li>Ovarian failure</li>
                <li>Diminished ovarian reserve</li>
                <li>Uterine vascular insufficiency</li>
                <li>Bladder malignancy</li>
              </ul>
            </div>
          </div>
          <div>
            <h3 style="color:var(--rose)"><i class="fas fa-heartbeat"></i> Surgery</h3>
            <div class="stat-card fragment" style="text-align:left; padding:14px">
              <strong>Nephrectomy:</strong>
              <ul class="small">
                <li>AKI in 71% during therapy</li>
                <li>CKD in 11&ndash;13% of survivors</li>
                <li>Hypertension risk</li>
                <li>Proteinuria in &gt;10%</li>
              </ul>
            </div>
            <div class="stat-card fragment" style="text-align:left; padding:14px; margin-top:10px">
              <strong>30&ndash;50 Year Mortality:</strong>
              <ul class="small">
                <li>75% excess deaths from:</li>
                <li><span class="highlight-rose">50% second malignancies</span><br>(bowel, breast cancers)</li>
                <li><span class="highlight-rose">25% cardiac disease</span></li>
              </ul>
            </div>
          </div>
        </div>
      </section>

      <!-- ============ QUIZ 6 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #6</h2>
        <div class="quiz-container" id="quiz6">
          <div class="quiz-question">A child with WAGR syndrome is being followed with surveillance. How often should screening ultrasounds be performed, and until what age?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz6')">
              <div class="option-letter">A</div>
              <div>Every 6 months until age 5</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz6')">
              <div class="option-letter">B</div>
              <div>Every 3 months until age 7</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz6')">
              <div class="option-letter">C</div>
              <div>Every 12 months until age 10</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz6')">
              <div class="option-letter">D</div>
              <div>Every 3 months until age 4</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz6-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 7 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #7</h2>
        <div class="quiz-container" id="quiz7">
          <div class="quiz-question">What is the most significant risk factor for surgical complications during Wilms tumor nephrectomy?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz7')">
              <div class="option-letter">A</div>
              <div>Tumor size greater than 10 cm</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz7')">
              <div class="option-letter">B</div>
              <div>IVC tumor thrombus extension</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz7')">
              <div class="option-letter">C</div>
              <div>General surgeon performing the nephrectomy (vs. pediatric surgeon)</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz7')">
              <div class="option-letter">D</div>
              <div>Bilateral disease</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz7-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 8 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #8</h2>
        <div class="quiz-container" id="quiz8">
          <div class="quiz-question">The most common histological subtype of renal cell carcinoma in children is:</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz8')">
              <div class="option-letter">A</div>
              <div>Clear cell RCC</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz8')">
              <div class="option-letter">B</div>
              <div>Translocation-type (MiT-RCC)</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz8')">
              <div class="option-letter">C</div>
              <div>Papillary RCC</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz8')">
              <div class="option-letter">D</div>
              <div>Chromophobe RCC</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz8-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 9 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #9</h2>
        <div class="quiz-container" id="quiz9">
          <div class="quiz-question">Diffuse anaplasia in Wilms tumor is associated with mutations in which gene?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz9')">
              <div class="option-letter">A</div>
              <div>WT1</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz9')">
              <div class="option-letter">B</div>
              <div>CTNNB1</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz9')">
              <div class="option-letter">C</div>
              <div>TP53</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz9')">
              <div class="option-letter">D</div>
              <div>SMARCB1</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz9-feedback"></div>
        </div>
      </section>

      <!-- ============ QUIZ 10 ============ -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Knowledge Check #10</h2>
        <div class="quiz-container" id="quiz10">
          <div class="quiz-question">During Wilms tumor nephrectomy, what is the recommended minimum number of lymph nodes to sample?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz10')">
              <div class="option-letter">A</div>
              <div>3 nodes</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'quiz10')">
              <div class="option-letter">B</div>
              <div>5 nodes</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz10')">
              <div class="option-letter">C</div>
              <div>7 nodes</div>
            </div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'quiz10')">
              <div class="option-letter">D</div>
              <div>12 nodes</div>
            </div>
          </div>
          <div class="quiz-feedback" id="quiz10-feedback"></div>
        </div>
      </section>

      <!-- ============ SECTION: ADVANCES ============ -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <div class="section-number">04</div>
        <span class="tag tag-purple">CUTTING EDGE</span>
        <h2>Recent Advances &amp;<br>Future Directions</h2>
      </section>

      <!-- Molecular Risk Stratification -->
      <section>
        <h2>Evolving Molecular Risk Stratification</h2>
        <div class="badge"><i class="fas fa-flask"></i> COG AREN2231</div>
        <div class="two-col">
          <div>
            <h3>COG AREN2231 Trial (Open)</h3>
            <ul class="small">
              <li class="fragment"><strong>Next-generation</strong> COG trial for favorable histology WT</li>
              <li class="fragment">Expanded molecular integration:
                <ul>
                  <li>LOH 11p15 (very low risk determination)</li>
                  <li>Combined LOH 1p + 16q</li>
                  <li>1q gain</li>
                  <li>Post-chemo histological response</li>
                </ul>
              </li>
              <li class="fragment"><strong>Modified Very Low Risk (mVLR):</strong> Nephrectomy-only if ZERO adverse biomarkers</li>
            </ul>
          </div>
          <div>
            <h3>Novel Molecular Targets</h3>
            <div class="timeline">
              <div class="timeline-item fragment">
                <div class="timeline-title">DROSHA / DGCR8</div>
                <div class="timeline-desc">miRNA microprocessor mutations &mdash; found in high-risk blastemal WT</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">SIX1 / SIX2</div>
                <div class="timeline-desc">Transcription factor mutations + miRNA pathway = worse outcomes</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">MYCN amplification</div>
                <div class="timeline-desc">Associated with aggressive disease phenotype</div>
              </div>
              <div class="timeline-item fragment">
                <div class="timeline-title">Circulating Tumor DNA</div>
                <div class="timeline-desc">COG AREN17B1-Q: detecting 1q gain and LOH from ctDNA &mdash; non-invasive monitoring</div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <!-- Targeted Therapies -->
      <section>
        <h2>Emerging Targeted &amp; Immunotherapies</h2>
        <table style="font-size:0.65em">
          <thead>
            <tr><th>Target / Pathway</th><th>Agent</th><th>Tumor</th><th>Status</th></tr>
          </thead>
          <tbody>
            <tr class="fragment">
              <td><strong>NTRK fusions</strong></td>
              <td><span class="highlight">Larotrectinib / Entrectinib</span></td>
              <td>Cellular CMN</td>
              <td><span class="tag tag-emerald">FDA-approved (tumor-agnostic)</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>EZH2</strong> (SMARCB1-loss)</td>
              <td><span class="highlight">Tazemetostat</span></td>
              <td>Rhabdoid tumor</td>
              <td><span class="tag tag-amber">Phase I &mdash; disease stabilization</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>VEGFR/TKI</strong></td>
              <td>Sunitinib, Cabozantinib</td>
              <td>Pediatric RCC</td>
              <td><span class="tag tag-teal">SIOP-RTSG UMBRELLA</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>IGF2 / IGF1R</strong></td>
              <td>Anti-IGF1R antibodies</td>
              <td>Wilms tumor</td>
              <td><span class="tag tag-purple">Preclinical</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>PI3K/AKT/mTOR</strong></td>
              <td>ZSTK474</td>
              <td>Wilms tumor</td>
              <td><span class="tag tag-purple">Preclinical</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>WT1-targeted</strong></td>
              <td>CAR-T cells / CTLs</td>
              <td>Wilms tumor</td>
              <td><span class="tag tag-amber">Phase I trials</span></td>
            </tr>
            <tr class="fragment">
              <td><strong>PD-1 + VEGFR</strong></td>
              <td>Pembrolizumab + Lenvatinib</td>
              <td>Renal medullary carcinoma</td>
              <td><span class="tag tag-amber">Dramatic responses reported</span></td>
            </tr>
          </tbody>
        </table>
        <div class="pearl-box fragment" style="margin-top:0.5em">
          <i class="fas fa-gem key-icon"></i> <strong>2024 Discovery:</strong> Variants in <strong>ALPK2, C16orf96, PRKDC, and SVIL</strong> identified via exome sequencing as strongly correlated with chemoresistance in advanced-stage Wilms tumor.
        </div>
      </section>

      <!-- Imaging Differential -->
      <section>
        <h2>Imaging: Key Differential Clues</h2>
        <table style="font-size:0.65em">
          <thead>
            <tr><th>Finding</th><th>Suggests</th><th>Key Feature</th></tr>
          </thead>
          <tbody>
            <tr class="fragment">
              <td><i class="fas fa-baby" style="color:var(--emerald)"></i> Neonatal solid renal mass</td>
              <td><strong>Mesoblastic nephroma</strong></td>
              <td>"Ring sign" on US, "double-layer sign" on CT</td>
            </tr>
            <tr class="fragment">
              <td><i class="fas fa-child" style="color:var(--teal)"></i> Child + "claw sign" + no calc</td>
              <td><strong>Wilms tumor</strong></td>
              <td>Heterogeneous, well-circumscribed, 9% calcification</td>
            </tr>
            <tr class="fragment">
              <td><i class="fas fa-bone" style="color:var(--amber)"></i> Renal mass + bone metastases</td>
              <td><strong>Clear cell sarcoma</strong></td>
              <td>Homogeneous, limited diffusion restriction</td>
            </tr>
            <tr class="fragment">
              <td><i class="fas fa-brain" style="color:var(--rose)"></i> Renal mass + subcapsular fluid + brain mass</td>
              <td><strong>Rhabdoid tumor</strong></td>
              <td>Curvilinear calcifications, central location</td>
            </tr>
            <tr class="fragment">
              <td><i class="fas fa-user" style="color:var(--purple)"></i> Adolescent + solid enhancing mass</td>
              <td><strong>RCC</strong></td>
              <td>25% calcification, older age group</td>
            </tr>
            <tr class="fragment">
              <td><i class="fas fa-exclamation-triangle" style="color:var(--slate)"></i> Crosses midline, encases vessels, 80%+ calc</td>
              <td><strong>Neuroblastoma</strong> (adrenal!)</td>
              <td>NOT renal origin &mdash; key differential</td>
            </tr>
          </tbody>
        </table>
        <div class="info-box fragment" style="margin-top:0.5em">
          <i class="fas fa-search" style="color:var(--teal)"></i> <strong>Always assess:</strong> IVC/renal vein tumor thrombus (4&ndash;10% of WT), contralateral kidney, lung metastases on chest CT. MRI superior for thrombus evaluation.
        </div>
      </section>

      <!-- ============ COMPARISON INFOGRAPHIC ============ -->
      <section>
        <h2>The Big Three: At a Glance</h2>
        <div class="img-container">
          <img src="assets/img/comparison-overview.png" alt="Pediatric Renal Masses: A Clinical Comparison">
        </div>
      </section>

      <!-- ============ COMPREHENSIVE COMPARISON TABLE ============ -->
      <section>
        <h2>Comprehensive Comparison</h2>
        <table style="font-size:0.6em">
          <thead>
            <tr><th>Feature</th><th style="color:var(--teal)">Wilms Tumor</th><th style="color:var(--emerald)">CMN</th><th style="color:var(--purple)">RCC</th><th style="color:var(--amber)">CCSK</th><th style="color:var(--rose)">MRTK</th></tr>
          </thead>
          <tbody>
            <tr><td><strong>Peak Age</strong></td><td>1&ndash;5 years</td><td>&lt;3 months</td><td>9&ndash;15 years</td><td>1&ndash;4 years</td><td>&lt;1 year</td></tr>
            <tr><td><strong>% of Pediatric Renal</strong></td><td>>90%</td><td>3&ndash;10%</td><td>2&ndash;6%</td><td>3&ndash;5%</td><td>1&ndash;2%</td></tr>
            <tr><td><strong>Key Genetics</strong></td><td>WT1, WT2, CTNNB1</td><td>ETV6-NTRK3, EGFR ITD</td><td>TFE3/TFEB fusions</td><td>BCOR ITD</td><td>SMARCB1/INI1 loss</td></tr>
            <tr><td><strong>Mets Pattern</strong></td><td>Lung &gt; liver</td><td>Rare</td><td>Lung, bone, liver</td><td><strong>Bone</strong> (23%)</td><td>Brain (AT/RT)</td></tr>
            <tr><td><strong>Primary Rx</strong></td><td>Surgery + chemo &plusmn; RT</td><td>Surgery alone</td><td>Surgery &plusmn; TKI</td><td>Surgery + chemo + RT</td><td>Multimodal (poor)</td></tr>
            <tr><td><strong>5-Year OS</strong></td><td>&gt;90%</td><td>96&ndash;100%</td><td>84.8%</td><td>~75%</td><td>~25%</td></tr>
          </tbody>
        </table>
      </section>

      <!-- ============ KEY TAKEAWAYS ============ -->
      <section>
        <h2><i class="fas fa-star" style="color:var(--amber)"></i> Key Takeaways</h2>
        <div style="font-size:0.9em">
          <div class="pearl-box fragment">
            <strong>1.</strong> Wilms tumor is the most common pediatric renal tumor (&gt;90%). Most present as healthy children with painless abdominal mass between ages 1&ndash;5.
          </div>
          <div class="pearl-box fragment">
            <strong>2.</strong> Age is your first filter: neonates &rarr; CMN, toddlers &rarr; Wilms, adolescents &rarr; RCC. Bone mets &rarr; CCSK. Brain + kidney tumor in infant &rarr; MRTK.
          </div>
          <div class="pearl-box fragment">
            <strong>3.</strong> COG and SIOP represent equally valid approaches with comparable survival. Know both frameworks.
          </div>
          <div class="pearl-box fragment">
            <strong>4.</strong> Molecular markers (1q gain, LOH 1p/16q, TP53) now drive treatment intensity decisions beyond stage and histology alone.
          </div>
          <div class="pearl-box fragment">
            <strong>5.</strong> General surgeons performing nephrectomy = 9x complication rate. These cases require pediatric surgical expertise. Minimum 5 lymph nodes sampled.
          </div>
          <div class="pearl-box fragment">
            <strong>6.</strong> Long-term survivor care is critical: 75% of excess deaths at 30&ndash;50 years from second cancers and cardiac disease.
          </div>
        </div>
      </section>

      <!-- ============ FINAL SCORE ============ -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <h2>Your Score</h2>
        <div id="final-score" style="font-size:4em; font-weight:900; margin:0.3em 0">
          <span id="final-correct">0</span>/<span id="final-total">10</span>
        </div>
        <div id="final-message" style="font-size:1.2em; color:var(--slate)">Complete the quizzes to see your score!</div>
        <div id="final-bar" style="max-width:400px; margin:1em auto">
          <div class="score-bar"><div class="score-bar-fill excellent" id="final-bar-fill" style="width:0%"></div></div>
        </div>
      </section>

      <!-- ============ REFERENCES ============ -->
      <section>
        <h2>Key References</h2>
        <div style="font-size:0.5em; columns: 2; column-gap: 30px; line-height:1.8; color:var(--slate)">
          <p>1. NCCN Clinical Practice Guidelines: Wilms Tumor (Nephroblastoma), Version 2.2025</p>
          <p>2. Espinoza AF, et al. Cancer Medicine. 2025;14(3):e70598</p>
          <p>3. Nakata K, et al. Int J Cancer. 2020;147(12):3313-3327</p>
          <p>4. Hol JA, et al. J Clin Oncol. 2022;40(17):1892-1902</p>
          <p>5. van der Beek JN, et al. Int J Cancer. 2021;148(11):2724-2735</p>
          <p>6. Denize T, et al. Histopathology. 2022;80(6):928-945</p>
          <p>7. Davick JJ, et al. Annals of Surgery. 2025</p>
          <p>8. Geller JI, et al. Cancer. 2020;126(23):5156-5164</p>
          <p>9. Sprokkerieft J, et al. Cancer Med. 2024;13(1):e6782</p>
          <p>10. Ritchey ML, et al. J Am Coll Surg. 2001;192(1):63-8</p>
          <p>11. Raymakers-Janssen PAMA, et al. Pediatr Nephrol. 2025;40(7):2393-2401</p>
          <p>12. Ssenyonga N, et al. Pediatr Blood Cancer. 2026;:e70061</p>
          <p>13. Vujani&#263; GM, et al. Int J Cancer. 2021;149(6):1332-1340</p>
          <p>14. Wong KF, et al. J Clin Oncol. 2016;34(15):1772-9</p>
          <p>15. COG Long-Term Follow-Up Guidelines. Hudson MM, et al. Pediatrics. 2021</p>
        </div>
      </section>

      <!-- ============ CLOSING ============ -->
      <section class="title-slide" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <h1 style="font-size:2em">Thank You</h1>
        <div class="subtitle">Questions &amp; Discussion</div>
        <div class="author" style="margin-top:1.5em">
          <strong>Mikael Petrosyan, MD, MBA, FACS, FAAP</strong>
          Division Chief, General &amp; Thoracic Surgery<br>
          Children's National Hospital<br><br>
          <span class="tag tag-teal"><i class="fab fa-youtube"></i> Surgucation</span>
          <span class="tag tag-purple"><i class="fas fa-globe"></i> surgucation.com</span>
        </div>
      </section>

    </div>
  </div>

  <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.js"></script>
  <script>
    // Initialize Reveal.js
    Reveal.initialize({
      hash: true,
      slideNumber: 'c/t',
      progress: true,
      controls: true,
      controlsTutorial: true,
      center: false,
      transition: 'slide',
      transitionSpeed: 'default',
      backgroundTransition: 'fade',
      width: 1280,
      height: 720,
      margin: 0.04,
      minScale: 0.2,
      maxScale: 2.0,
      pdfSeparateFragments: false,
    });

    // Quiz system
    let score = 0;
    let totalAnswered = 0;
    const totalQuestions = 10;
    const answered = {};

    const explanations = {
      quiz1: {
        correct: "Correct! A healthy-appearing child with a firm, non-tender abdominal mass, claw sign on CT, and minimal calcification is the classic presentation of Wilms tumor. Neuroblastoma patients are typically ill-appearing with 60-70% calcification.",
        incorrect: "The answer is <strong>Wilms tumor</strong>. Key clues: healthy-appearing child (age 3), firm non-tender mass found incidentally, claw sign (intrarenal origin), no calcification. Neuroblastoma children appear ill with 60-70% calcification. CMN presents in infants <3 months. RCC typically presents in adolescents 9-15 years."
      },
      quiz2: {
        correct: "Correct! Per COG staging, a tumor biopsied before removal is automatically Stage III, regardless of other findings. This is a commonly tested point!",
        incorrect: "The answer is <strong>Stage III</strong>. Per COG criteria, Stage III includes: tumor biopsied before removal, lymph node involvement, peritoneal implants, tumor spillage, or tumor removed in more than one piece. Biopsy before removal automatically upgrades to Stage III."
      },
      quiz3: {
        correct: "Correct! CMN is the most common renal tumor in infants under 3 months of age. At 2 months old, this is the most likely diagnosis. Wilms typically presents at 1-5 years.",
        incorrect: "The answer is <strong>Congenital mesoblastic nephroma</strong>. CMN is the most common renal tumor in infants under 3 months (median age 1 month). Wilms tumor peaks at 1-5 years, RCC in adolescents 9-15 years, and clear cell sarcoma at 1-4 years."
      },
      quiz4: {
        correct: "Correct! Clear cell sarcoma of the kidney is known as the 'bone-metastasizing renal tumor of childhood.' BCOR ITD is found in 85% of cases. Always get a bone scan!",
        incorrect: "The answer is <strong>Clear cell sarcoma of the kidney</strong>. CCSK is known as the 'bone-metastasizing renal tumor of childhood' with 23% developing bone metastases (spine, pelvis, ribs). This is driven by BCOR internal tandem duplications found in 85% of cases."
      },
      quiz5: {
        correct: "Correct! Rhabdoid tumors are characterized by SMARCB1/INI1 loss on chromosome 22q11.2. ~25% have synchronous brain tumors (AT/RT). Always get a brain MRI!",
        incorrect: "The answer is <strong>SMARCB1/INI1 loss</strong> (chromosome 22q11.2). WT1 = Wilms tumor. BCOR ITD = clear cell sarcoma. ETV6-NTRK3 fusion = cellular CMN. SMARCB1/INI1 loss is the hallmark of rhabdoid tumor."
      },
      quiz6: {
        correct: "Correct! Children with WAGR and other high-risk syndromes should have physical exam + renal US every 3 months until age 7. Rationale: 90-98% of tumors in these syndromes occur by age 7.",
        incorrect: "The answer is <strong>every 3 months until age 7</strong>. Per NCCN guidelines, high-risk syndromes (WAGR, Denys-Drash, BWS) require Q3-month ultrasound surveillance until age 7, as 90-98% of WT in these patients occurs by this age."
      },
      quiz7: {
        correct: "Correct! Having a general surgeon perform the nephrectomy vs. a pediatric surgeon carries an OR of 9.0 for complications  the single highest risk factor. This underscores the importance of pediatric surgical expertise.",
        incorrect: "The answer is <strong>general surgeon performing the nephrectomy</strong> (OR 9.0). While IVC extension (OR 3.8), flank incision (OR 5.3), and tumor 10cm (OR 2.0) are all risk factors, the surgeon type carries the highest odds ratio at 9.0."
      },
      quiz8: {
        correct: "Correct! MiT-RCC (TFE3/TFEB translocation type) accounts for 36-56% of pediatric RCC, unlike adults where clear cell predominates (~70%). This is a critical distinction.",
        incorrect: "The answer is <strong>Translocation-type (MiT-RCC)</strong>. In children, MiT-RCC accounts for 36-56% of cases, followed by papillary (20-30%) and clear cell (6-23%). This differs markedly from adults, where clear cell RCC is predominant (~70%)."
      },
      quiz9: {
        correct: "Correct! Anaplasia (both focal and diffuse) is associated with somatic TP53 mutations and predicts chemoresistance and poor prognosis, especially diffuse anaplasia in advanced stages.",
        incorrect: "The answer is <strong>TP53</strong>. Diffuse anaplasia in Wilms tumor is characterized by TP53 mutations, which confer chemoresistance. WT1 is associated with WAGR/Denys-Drash syndromes. CTNNB1 is a Wnt pathway mutation. SMARCB1 is associated with rhabdoid tumor."
      },
      quiz10: {
        correct: "Correct! COG recommends sampling a minimum of 5 lymph nodes from the renal hilum, pericaval, and para-aortic regions for accurate staging. Inadequate sampling may under-stage the tumor.",
        incorrect: "The answer is <strong>5 nodes</strong>. Per COG/NCCN guidelines, a minimum of 5 lymph nodes should be sampled from the renal hilum, pericaval, and para-aortic regions. This is essential for accurate staging and treatment planning."
      }
    };

    function checkAnswer(el, isCorrect, quizId) {
      if (answered[quizId]) return;
      answered[quizId] = true;
      totalAnswered++;

      const options = el.parentElement.querySelectorAll('.quiz-option');
      options.forEach(opt => {
        opt.style.pointerEvents = 'none';
      });

      const feedback = document.getElementById(quizId + '-feedback');

      if (isCorrect) {
        score++;
        el.classList.add('correct');
        feedback.className = 'quiz-feedback show correct-fb';
        feedback.innerHTML = '<i class="fas fa-check-circle"></i> ' + explanations[quizId].correct;
      } else {
        el.classList.add('incorrect');
        // Highlight the correct answer
        options.forEach(opt => {
          if (opt.onclick.toString().includes('true')) {
            opt.classList.add('correct');
          }
        });
        feedback.className = 'quiz-feedback show incorrect-fb';
        feedback.innerHTML = '<i class="fas fa-times-circle"></i> ' + explanations[quizId].incorrect;
      }

      // Update score tracker
      document.getElementById('quiz-score').textContent = score;
      document.getElementById('quiz-total').textContent = totalAnswered;
      document.getElementById('score-tracker').style.display = 'block';

      // Update final score
      document.getElementById('final-correct').textContent = score;
      document.getElementById('final-total').textContent = totalQuestions;
      const pct = (score / totalQuestions) * 100;
      document.getElementById('final-bar-fill').style.width = pct + '%';

      if (totalAnswered === totalQuestions) {
        let msg = '';
        if (pct >= 90) msg = 'Outstanding! You have mastered pediatric renal masses!';
        else if (pct >= 70) msg = 'Great job! Review the topics you missed for a deeper understanding.';
        else if (pct >= 50) msg = 'Good effort! Consider reviewing the key sections again.';
        else msg = 'Keep studying! Review the presentation materials and try again.';
        document.getElementById('final-message').textContent = msg;
      }
    }

    // Keyboard shortcut to toggle score
    document.addEventListener('keydown', function(e) {
      if (e.key === 's' && !e.ctrlKey && !e.metaKey) {
        const tracker = document.getElementById('score-tracker');
        tracker.style.display = tracker.style.display === 'none' ? 'block' : 'none';
      }
    });
  </script>
</body>
</html>
